Is Foundayo or Mounjaro better for weight loss?

Foundayo reports 11.1% average weight loss and Mounjaro 11.9%, each from its own trial. The two were not compared against each other, so the higher figure is not a result of a head-to-head and this page does not present it as one. What is comparable is what each costs, below.

Which is cheaper, Foundayo or Mounjaro?

Foundayo, at $299 a month against $499 — a difference of $200 a month, or $2,899 over a year counting 12 fills a year for Foundayo and 13 for Mounjaro. Both figures are the maintenance price rather than an introductory rate.

Can you switch between Foundayo and Mounjaro?

They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.

← All providers and medications

Foundayo (orforglipron) vs Mounjaro (tirzepatide, diabetes label)

Verdict

Foundayo is the better choice of the two, winning on entry price (halfrx score 6.3 against 5.1).

Computed from the stored fields, so it moves when a price does. Nothing here is written by hand or by a model.

Which is cheaper, Foundayo (orforglipron) or Mounjaro (tirzepatide, diabetes label)?

Foundayo (orforglipron) is $149–$349 a month all-in, read from its own page on 2026-09-12; Mounjaro (tirzepatide, diabetes label) is $499, read from its own page on 2026-09-21. At the maintenance dose the gap is $200 a month, which is $2,899 across a year, counting 12 fills for Foundayo (orforglipron) and 13 for Mounjaro (tirzepatide, diabetes label). Trial weight loss was 11.1% against 11.9%, from separate trials with different populations, so the gap is not a measured difference between the two. Every axis below is computed from stored fields rather than written by hand, so the comparison moves when a price does. They were last checked on 2026-09-12 and 2026-09-21. Neither carries an FTC action, a state action, a BBB F grade or an FDA warning letter. The published formula scores them 6.3 and 5.1 out of 10, arithmetic over the same stored fields rather than an editor's preference.

Head to head

Foundayo (orforglipron) against Mounjaro (tirzepatide, diabetes label), one row per axis, with the side that wins each axis marked.
What decides it	Foundayo $149–$349/mo	Mounjaro $499/mo
Entry priceFoundayo (orforglipron) is $350/mo cheaper to start — $149 against $499.	✓ better here	—
Regulatory and complaint riskNeither carries a lawsuit, an FDA warning letter or a supply-risk flag.	tied	tied
Average weight loss in trialsFoundayo (orforglipron) reports 11.1% and Mounjaro (tirzepatide, diabetes label) 11.9%, each from its own trial. They were not compared against each other, and the populations, durations and endpoints differ, so the higher number is not a better result — it is a different study.	not comparable	not comparable

What the trials, the titration and a year actually say

Axis	Foundayo	Mounjaro
Mean weight loss in the cited trial	11.1%	11.9%
The trial that figure comes from	ATTAIN-1, Trial 1 on the label, 72 weeks: 11.1% mean weight loss at 17.2 mg against 2.1% on placebo, intention-to-treat.	No percentage of body weight appears anywhere on the Mounjaro label, which has no weight-management section: every trial on it is a diabetes trial and reports weight in kilograms. This figure is worked out from the label's own kilograms — 11.2 kg lost from a 93.8 kg mean baseline at week 40 on 15 mg, in SURPASS-2 against semaglutide — and is an arithmetic step the label does not take.
Maintenance dose	5.5 mg, 9 mg, 14.5 mg or 17.2 mg daily	2.5 mg to 15 mg once weekly, set by blood sugar control
Earliest week you reach it	week 9	—
Year one at the published price of every step	$3,188	$6,487

Trial percentages are quoted from the label or the named trial beside them. They are not a head-to-head result: different populations, different durations, different endpoints. That is why the comparison above scores this axis as not comparable rather than awarding it to the higher number. The year-one figures walk each titration step at its published price — Mounjaro has one price at every dose, so there is no step to walk — and count the fills each manufacturer bills a year: 12 for Foundayo, 13 for Mounjaro. The full arithmetic is published.

Go to Foundayo ↗Go to Mounjaro ↗

Read the price gap carefully: these two are not the same purchase

These are different molecules — orforglipron against tirzepatide — so this is a comparison of two treatments, not of two prices for one.
Against every medication on this site with a verified maintenance price, Foundayo (orforglipron) is the 3rd cheapest of 9 and Mounjaro (tirzepatide, diabetes label) the 9th — the cheapest of them all is $75.

Eli Lilly

Foundayo (orforglipron)

6.3

$149–$349/mo all-in

verified 2026-09-12

Newly approvedPrice conditional on refill timingBoxed warning

Eli Lilly

Mounjaro (tirzepatide, diabetes label)

5.1

$499/mo all-in

verified 2026-09-21

Off-label for weightBoxed warning

Foundayo (orforglipron)

Pros

+A daily pill with no injection, no needles and no refrigeration — unlike semaglutide pills it is a small molecule, so there are no food-and-water timing rules to follow.[3]
+$149 a month at the entry dose through LillyDirect — the lowest self-pay price for a branded GLP-1 on this site, matched only by the Wegovy pill's first month.[4]
+11.1% mean weight loss over 72 weeks in ATTAIN-1, intention-to-treat — below the Wegovy tablet's 13.6%, and well above the older oral options.[2]
+Being a small molecule, it is manufactured chemically rather than biologically — supply scales in a way peptide injectables cannot.[3]
+Commercially insured with coverage, Lilly's card can bring it to as little as $25 a month.[1]

Cons

−Approved 1 April 2026, so real-world safety data outside trials is still thin compared with semaglutide's years of use.[2]
−$649 list price if you have no coverage and do not use the LillyDirect self-pay channel.[4]
−Weight loss trails tirzepatide injection, which reaches roughly 20%+ in its pivotal trials.[2]
−Maintenance doses hold their $299 price only while you refill within 45 days; lapse and they are $349.[1]

Sources

Mounjaro (tirzepatide, diabetes label)

Pros

+Same tirzepatide molecule as Zepbound, the most effective approved weight-loss agent.[4]
+On-label and readily covered if you have type 2 diabetes.[4]

Cons

−Off-label for weight loss without diabetes — expect insurance denial and prescriber reluctance.[4]
−Self-pay is $499 a month at every strength through LillyDirect, with no cheaper starting tier: Zepbound, the same molecule on the weight-loss label, is $299 at 2.5 mg and $449 at 7.5 mg and above through the same pharmacy. For weight loss, Zepbound is the cheaper route to the same molecule.[1]
−Weekly injection with the same GI side-effect profile.[4]

Sources

Foundayo side effects →Mounjaro side effects →Foundayo dosage →Mounjaro dosage →

Comparisons are computed from the fields on each card, not written by hand or by a model, so they change when the data does. Information only, not medical advice. halfrx may earn a commission from some links, which never changes what a comparison says.

Everything on Foundayo

Everything on Mounjaro

Foundayo against Mounjaro, answered

Is Foundayo or Mounjaro better for weight loss?: Foundayo reports 11.1% average weight loss and Mounjaro 11.9%, each from its own trial. The two were not compared against each other, so the higher figure is not a result of a head-to-head and this page does not present it as one. What is comparable is what each costs, below.
Which is cheaper, Foundayo or Mounjaro?: Foundayo, at $299 a month against $499 — a difference of $200 a month, or $2,899 over a year counting 12 fills a year for Foundayo and 13 for Mounjaro. Both figures are the maintenance price rather than an introductory rate.
Can you switch between Foundayo and Mounjaro?: They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.